FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986462840> ?p ?o ?g. }

• W1986462840 endingPage "93" @default.
• W1986462840 startingPage "83" @default.
• W1986462840 abstract "Reovirus preferentially infects and kills cancer cells and is currently undergoing clinical trials internationally. While oncolysis is the primary mode of tumour elimination, increasing evidence illustrates that reovirus additionally stimulates anti-tumour immunity with a capacity to target existing and possibly relapsing cancer cells. These virus-induced anti-tumour immune activities largely determine the efficacy of oncotherapy. On the other hand, anti-viral immune responses can negatively affect oncotherapy. Hence, the strategic management of anti-tumour and anti-viral immune responses through complementary therapeutics is crucial to achieve the maximum anti-cancer benefits of oncotherapy.Intra-peritoneal injection of mouse ovarian surface epithelial cells (ID8 cells) into wild-type C57BL/6 mice was treated with a therapeutic regimen of reovirus and/or gemcitabine and then analysed for prolonged survival, disease pathology, and various immunological parameters. Furthermore, in vitro analyses were conducted to assess apoptosis, viral spread, and viral production during reovirus and/or gemcitabine treatment.We demonstrate that reovirus and gemcitabine combination treatment postpones peritoneal carcinomatosis development and prolongs the survival of cancer-bearing hosts. Importantly, these anti-cancer benefits are generated through various immunological mechanisms, including: (1) inhibition of myeloid-derived suppressor cells recruitment to the tumour microenvironment, (2) downmodulation of pro-MDSC factors, and (3) accelerated development of anti-tumour T-cell responses.The complementation of reovirus with gemcitabine further potentiates virus-initiated anti-cancer immunity and enhances the efficacy of oncotherapy. In the context of ongoing clinical trials, our findings represent clinically relevant information capable of enhancing cancer outcomes." @default.
• W1986462840 created "2016-06-24" @default.
• W1986462840 creator A5004261817 @default.
• W1986462840 creator A5010311592 @default.
• W1986462840 creator A5025029978 @default.
• W1986462840 creator A5029393495 @default.
• W1986462840 creator A5088287164 @default.
• W1986462840 creator A5090850043 @default.
• W1986462840 date "2013-11-26" @default.
• W1986462840 modified "2023-10-12" @default.
• W1986462840 title "Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms" @default.
• W1986462840 cites W1494453913 @default.
• W1986462840 cites W1854596437 @default.
• W1986462840 cites W1979127187 @default.
• W1986462840 cites W1996538874 @default.
• W1986462840 cites W1998044332 @default.
• W1986462840 cites W2023310830 @default.
• W1986462840 cites W2024040080 @default.
• W1986462840 cites W2038820904 @default.
• W1986462840 cites W2052783145 @default.
• W1986462840 cites W2052874737 @default.
• W1986462840 cites W2059492353 @default.
• W1986462840 cites W2071651938 @default.
• W1986462840 cites W2074799207 @default.
• W1986462840 cites W2077376170 @default.
• W1986462840 cites W2083467141 @default.
• W1986462840 cites W2090599158 @default.
• W1986462840 cites W2096216990 @default.
• W1986462840 cites W2102833781 @default.
• W1986462840 cites W2105459360 @default.
• W1986462840 cites W2107277218 @default.
• W1986462840 cites W2111415894 @default.
• W1986462840 cites W2111954625 @default.
• W1986462840 cites W2113313714 @default.
• W1986462840 cites W2119677763 @default.
• W1986462840 cites W2120067300 @default.
• W1986462840 cites W2127839329 @default.
• W1986462840 cites W2128892990 @default.
• W1986462840 cites W2136911804 @default.
• W1986462840 cites W2139397653 @default.
• W1986462840 cites W2145994992 @default.
• W1986462840 cites W2147621051 @default.
• W1986462840 cites W2148676724 @default.
• W1986462840 cites W2151488185 @default.
• W1986462840 cites W2157269800 @default.
• W1986462840 cites W2160390319 @default.
• W1986462840 cites W2163045779 @default.
• W1986462840 cites W2168295595 @default.
• W1986462840 cites W2169991956 @default.
• W1986462840 cites W2171249989 @default.
• W1986462840 cites W2171283491 @default.
• W1986462840 cites W2322282426 @default.
• W1986462840 cites W4240051020 @default.
• W1986462840 doi "https://doi.org/10.1038/bjc.2013.695" @default.
• W1986462840 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3887295" @default.
• W1986462840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24281006" @default.
• W1986462840 hasPublicationYear "2013" @default.
• W1986462840 type Work @default.
• W1986462840 sameAs 1986462840 @default.
• W1986462840 citedByCount "55" @default.
• W1986462840 countsByYear W19864628402014 @default.
• W1986462840 countsByYear W19864628402015 @default.
• W1986462840 countsByYear W19864628402016 @default.
• W1986462840 countsByYear W19864628402017 @default.
• W1986462840 countsByYear W19864628402018 @default.
• W1986462840 countsByYear W19864628402019 @default.
• W1986462840 countsByYear W19864628402020 @default.
• W1986462840 countsByYear W19864628402021 @default.
• W1986462840 countsByYear W19864628402022 @default.
• W1986462840 countsByYear W19864628402023 @default.
• W1986462840 crossrefType "journal-article" @default.
• W1986462840 hasAuthorship W1986462840A5004261817 @default.
• W1986462840 hasAuthorship W1986462840A5010311592 @default.
• W1986462840 hasAuthorship W1986462840A5025029978 @default.
• W1986462840 hasAuthorship W1986462840A5029393495 @default.
• W1986462840 hasAuthorship W1986462840A5088287164 @default.
• W1986462840 hasAuthorship W1986462840A5090850043 @default.
• W1986462840 hasBestOaLocation W19864628401 @default.
• W1986462840 hasConcept C121608353 @default.
• W1986462840 hasConcept C126322002 @default.
• W1986462840 hasConcept C151730666 @default.
• W1986462840 hasConcept C203014093 @default.
• W1986462840 hasConcept C2776107976 @default.
• W1986462840 hasConcept C2779343474 @default.
• W1986462840 hasConcept C2780258809 @default.
• W1986462840 hasConcept C502942594 @default.
• W1986462840 hasConcept C71924100 @default.
• W1986462840 hasConcept C82210918 @default.
• W1986462840 hasConcept C86803240 @default.
• W1986462840 hasConcept C8891405 @default.
• W1986462840 hasConceptScore W1986462840C121608353 @default.
• W1986462840 hasConceptScore W1986462840C126322002 @default.
• W1986462840 hasConceptScore W1986462840C151730666 @default.
• W1986462840 hasConceptScore W1986462840C203014093 @default.
• W1986462840 hasConceptScore W1986462840C2776107976 @default.
• W1986462840 hasConceptScore W1986462840C2779343474 @default.
• W1986462840 hasConceptScore W1986462840C2780258809 @default.
• W1986462840 hasConceptScore W1986462840C502942594 @default.

• next